Names and pronunciation
(toe′fa-sye′ti-nib) Xeljanz, Xeljanz XR
Source page 1308
Loading InternPractice…
Individual generic drug information
Extracted information for tofacitinib only.
(toe′fa-sye′ti-nib) Xeljanz, Xeljanz XR
Source page 1308
Func. class.: Antirheumatic agent (disease modifying), immunomodula- tor/biologic DMARD
Source page 1308
Chem. class.: Janus kinase inhibitor
Source page 1308
ACTION: Affects the signaling pathway of Janus kinase
Source page 1308
USES: Rheumatoid arthritis (moderately to severely active) in those who have taken methotrexate with inadequate response or intolerance, juvenile arthritis
Source page 1308
Extracted information for tofacitinib only.
CONTRAINDICATIONS: Hyper- sensitivity Precautions: Pregnancy, breastfeeding, neonates, infants, children, geriatric patients, neoplastic disease, ulcerative coli- tis, neutropenia, peptic ulcer disease, active infections, risk of lymphomas/leukemias, TB, posttransplant lymphoproliferative dis- order (PTLD), kidney disease, diabetes mellitus, HIV, hypercholesterolemia, herpes virus infection reactivation, Asian patients
Source page 1308
Black Box Warning: Infection, secondary malignancy Black Box Warning: Do not use with TNF modifiers, vaccines, potent immunosup- pressants, other biologic DMARDS; seri- ous infections may occur Increase: tofacinib effect—CYP3A4 inhib- itors (amprenavir, boceprevir, delavirdine, ketoconazole, indinavir, itraconazole, dal- fopristin/quinupristin, ritonavir, tipranavir, fluconazole, isoniazid, miconazole) Decrease: tofacinib effect—CYP3A4 inducers (rifAMPin, rifapentine, rifabutin, primidone, phenytoin, PHENobarbital, nevirapine, nafcillin, modafinil, griseoful- vin, etravirine, efavirenz, barbiturates, bexarotene, bosentan, carBAMazepine, enzalutamide, dexamethasone) Drug/Lab Test Increase: LFTs, cholesterol Decrease: neutrophils, lymphocytes, Hct, HB Black Box Warning: Active infection, including localized infection: evaluate for latent or active TB before use; treat with antimycobacterials before use; may cause serious fatal infections (pulmonary or extrapulmonary TB; invasive fungal infections; and bacterial, viral, and op- portunistic infections); during and after use, monitor for infection including TB in those who tested negative for latent TB before use; if a serious infection devel- ops, interrupt receipt until the infection is controlled, reactivation of viral infections is higher in Asian patients Black Box Warning: Secondary ma- lignancy: lymphoma and other malig- nancies have been noted with product use • Epstein-Barr virus–associated post- transplant lymphoproliferative disor- der (PTLD): in kidney transplant patients when used with this product and immu nosuppressives • Liver disease: not recommended in severe liver disease, impairment; dose modification is needed with moderate liver impairment, monitor LFTs • GI perforation: assess in those with diverticulitis, peptic ulcer disease, or ul cerative colitis Black Box Warning: Immunosuppres- sion: obtain neutrophil and lymphocyte counts before use; do not start the prod- uct in lymphocyte count <500 cells/mm3 or ANC <1000 cells/mm3; for ANC >1000 cells/mm3, monitor neutrophil counts after 4-8 wk and every 3 mo thereafter; lymphocyte count >500 cells/mm3, mon- itor lymphocyte counts every 3 mo • Anemia: determine HB, do not start in HB <9 g/dL; in HB ≥9 g/dL, monitor HB af ter 4-8 wk and every 3 mo thereafter • Pregnancy/breastfeeding: use dur ing pregnancy only if the potential benefit justifies the potential risk to the fetus; if pregnancy occurs, enrollment in the preg nancy registry is encouraged by calling T 1-877-311-8972; discontinue product or breastfeeding; serious adverse reactions can occur in nursing infants Black Box Warning: Neoplastic disease (lymphomas/leukemias)
Source pages 1308, 1309
SIDE EFFECTS CNS: Headache, paresthesias, insomnia, fatigue CV: Hypertension, increased PR interval GI: Abdominal pain, nausea, liver dam age, dyspepsia, vomiting, diarrhea, gas- tritis, GI perforation, steatosis HEMA: Anemia, lymphocytosis, lympho- penia, neutropenia INTEG: Rash, pruritus, angioedema MISC: Increased cancer risk, risk of infection (TB, invasive fungal infections, other opportunistic infections), may be fatal, posttransplant lymphoproliferative disorder (PTLD), osteoarthritis
Source page 1308
INTERACTIONS
Source page 1309
Extracted information for tofacitinib only.
DOSAGE AND ROUTES Psoriatic arthritis • Adult: PO 5 mg bid with a DMARD if receiving potent CYP3A4 inhibitor, 5 mg/ day if receiving moderate CYP3A4 inhibi- tor and 2C19 inhibitors; EXT REL 11 mg/day with a DMARD Moderate to severe rheumatoid arthritis • Adult: PO 5 mg bid with or without methotrexate or a DMARD; EXT REL 11 mg/day Juvenile arthritis • Child ≥2 yr and ≥10 kg/adolescents: PO 10-20 kg: PO solution 3.2 mg bid; 20-40 kg: 4 mg bid; ≥40 kg (solution/ tablet) 5 mg bid Ulcerative colitis • Adult: PO 10 mg bid × 8 wk or more, then 5 or 10 mg bid (immediate release)
Source page 1308
Available forms: Tabs 5 mg; ext rel tab 11 mg; oral solution
Source page 1308
Administer: PO route • Without regard to food • Do not chew, crush, split XR tablet, swallow whole • Do not take missed dose, resume nor- mal schedule
Source page 1308
Extracted information for tofacitinib only.
Assess: • Monitor lipid profile, Hct/HB, WBC, LFTs • RA: Pain, stiffness, ROM, swelling of joints before, during treatment
Source page 1309
Evaluate: • Therapeutic response: decreased in- flammation, pain in joints, decreased joint destruction
Source page 1309
CLINICAL CONSIDERATIONS
Source page 1309
Patient and caregiver information: • Not to take any live virus vaccines dur- ing treatment; vaccines should be brought up-to-date before starting treatment • To report signs of infection, allergic reaction • Pregnancy: to report if pregnancy is planned or suspected; not to breastfeed
Source page 1310
Extracted information for tofacitinib only.
PHARMACOKINETICS Bioavailability 70%, protein binding 40% (albumin), metabolism mediated by CYP3A4, half-life 3 hr, peak 0.5-1 hr
Source page 1309
Filter the extracted dose blocks for this individual drug.
Psoriatic arthritis
• Adult: PO 5 mg bid with a DMARD if receiving potent CYP3A4 inhibitor, 5 mg/ day if receiving moderate CYP3A4 inhibi- tor and 2C19 inhibitors; EXT REL 11 mg/day with a DMARD Moderate to severe rheumatoid arthritis
Candidate age grouping · source page 1308
Psoriatic arthritis
• Adult: PO 5 mg bid with or without methotrexate or a DMARD; EXT REL 11 mg/day Juvenile arthritis
Candidate age grouping · source page 1308
Psoriatic arthritis
• Child ≥2 yr and ≥10 kg/adolescents: PO 10-20 kg: PO solution 3.2 mg bid; 20-40 kg: 4 mg bid; ≥40 kg (solution/ tablet) 5 mg bid Ulcerative colitis
Candidate age grouping · source page 1308
Psoriatic arthritis
• Adult: PO 10 mg bid × 8 wk or more, then 5 or 10 mg bid (immediate release)
Candidate age grouping · source page 1308